News Releases
Aug 12, 2022
Axcella Reports Second Quarter Financial Results and Provides Business Update
Aug 02, 2022
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
May 26, 2022
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
May 19, 2022
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 05, 2022
Axcella Reports First Quarter Financial Results and Provides Business Update
Mar 30, 2022
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Mar 23, 2022
Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
Mar 16, 2022
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
Feb 14, 2022
Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH
Feb 10, 2022
Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference
Displaying 1 - 10 of 13